Considerations before the decision-making including fluvoxamine as a treatment option in guidelines on the management of COVID-19.

Zhao, Yan-Jie; Jin, Yu; Zhang, Qinge; Su, Zhaohui; Cheung, Teris; Zheng, Wei; Ng, Chee H; Xiang, Yu-Tao

Zhao, Yan-Jie; Jin, Yu; Zhang, Qinge; Su, Zhaohui; Cheung, Teris; Zheng, Wei; Ng, Chee H; Xiang, Yu-Tao.

Zhao YJ; Unit of Psychiatry, Department of Public Health and Medicinal Administration, & Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macao SAR, China.
Jin Y; Centre for Cognitive and Brain Sciences, University of Macau, Macao SAR, China.
Zhang Q; Institute of Advanced Studies in Humanities and Social Sciences, University of Macau, Macao SAR, China.
Su Z; College of Education for the Future, Beijing Normal University, Beijing, China.
Cheung T; The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital & the Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.
Zheng W; Center on Smart and Connected Health Technologies, Mays Cancer Center, School of Nursing, UT Health San Antonio, San Antonio, Texas, USA.
Ng CH; School of Nursing, Hong Kong Polytechnic University, Hong Kong SAR, China.
Xiang YT; The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China.

Psychol Med ; : 1-2, 2022 Feb 16.

Article in English | MEDLINE | ID: covidwho-1692718

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Psychol Med Year: 2022 Document Type: Article Affiliation country: S0033291722000022

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google